X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (54) 54
grazoprevir mk-5172 (49) 49
ribavirin (44) 44
humans (43) 43
hepatitis c (42) 42
hepatitis c virus (42) 42
elbasvir mk-8742 (39) 39
treatment-naive (38) 38
hepatitis (34) 34
pharmacology & pharmacy (30) 30
antiviral agents - therapeutic use (29) 29
genotype 1 infection (28) 28
grazoprevir (28) 28
safety (28) 28
combination therapy (27) 27
hepatitis c, chronic - drug therapy (26) 26
treatment-experienced patients (26) 26
efficacy (25) 25
gastroenterology & hepatology (25) 25
interferon (25) 25
elbasvir (24) 24
infections (23) 23
mk-5172 (22) 22
hepacivirus - drug effects (20) 20
infectious diseases (20) 20
label phase-2 trial (20) 20
antiviral agents (19) 19
hepatitis-c virus (19) 19
male (18) 18
coinfection (17) 17
female (17) 17
hepatitis c - drug therapy (16) 16
human immunodeficiency virus--hiv (16) 16
infection (16) 16
virus genotype 1 (16) 16
adult (15) 15
antiviral agents - adverse effects (15) 15
clinical trials (15) 15
drug therapy, combination (15) 15
genotype (15) 15
middle aged (15) 15
open-label (15) 15
genotypes (14) 14
mk-8742 (14) 14
sofosbuvir (14) 14
viruses (14) 14
drug therapy (13) 13
ns3/4a protease (13) 13
virus diseases (13) 13
antiviral agents - administration & dosage (12) 12
cirrhosis (12) 12
drug dosages (12) 12
genotype & phenotype (12) 12
health aspects (12) 12
hepacivirus - genetics (12) 12
microbiology (12) 12
patients (12) 12
virology (12) 12
hcv (11) 11
hiv (11) 11
hiv infections - complications (11) 11
imidazoles - therapeutic use (11) 11
liver cirrhosis (11) 11
treatment outcome (11) 11
aged (10) 10
analysis (10) 10
care and treatment (10) 10
chronic infection (10) 10
drug combinations (10) 10
drug interactions (10) 10
hcv ns5a inhibitor (10) 10
hepatology (10) 10
pharmacokinetics (10) 10
pharmacology (10) 10
treatment-naive patients (10) 10
antiviral agents - pharmacokinetics (9) 9
benzofurans - administration & dosage (9) 9
benzofurans - therapeutic use (9) 9
imidazoles - administration & dosage (9) 9
liver (9) 9
quinoxalines - administration & dosage (9) 9
quinoxalines - therapeutic use (9) 9
sustained virological response (9) 9
young adult (9) 9
animals (8) 8
antiviral agents - pharmacology (8) 8
benzofurans - pharmacokinetics (8) 8
combination (8) 8
daclatasvir plus sofosbuvir (8) 8
direct-acting antivirals (8) 8
hepatitis c, chronic - complications (8) 8
hiv infections - drug therapy (8) 8
imidazoles - adverse effects (8) 8
imidazoles - pharmacokinetics (8) 8
internal medicine (8) 8
ns5a (8) 8
pegylated interferon (8) 8
quinoxalines - adverse effects (8) 8
quinoxalines - pharmacokinetics (8) 8
research (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 714 - 725
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 11/2016, Volume 165, Issue 9, pp. 625 - 634
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 11/2015, Volume 59, Issue 11, pp. 6922 - 6929
Elbasvir is an investigational NS5A inhibitor with in vitro activity against multiple HCV genotypes. Antiviral activity of elbasvir was measured in replicons... 
MK-8742 | EFFICACY | GRAZOPREVIR MK-5172 | SAFETY | COMBINATION THERAPY | RESISTANCE | ANTIVIRAL ACTIVITY | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTION | PHASE-2 | RIBAVIRIN | Hepacivirus - drug effects | Humans | Middle Aged | Hepacivirus - genetics | Benzofurans - pharmacology | Genotype | Male | Imidazoles - pharmacology | Young Adult | Adolescent | Adult | Female | Replicon - genetics | Antiviral Agents
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 06/2018, Volume 113, Issue 6, pp. 863 - 871
OBJECTIVES: Although direct-acting antiviral regimens have dramatically improved the treatment of hepatitis C virus (HCV) infection, there is some evidence... 
TREATMENT-NAIVE | EFFICACY | GRAZOPREVIR MK-5172 | SAFETY | COMBINATION THERAPY | TREATMENT-EXPERIENCED PATIENTS | GENOTYPE 1 INFECTION | ELBASVIR MK-8742 | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | PEGINTERFERON | Clinical trials | Hepatitis | Infections | Interferon
Journal Article
JOURNAL OF VIRAL HEPATITIS, ISSN 1352-0504, 05/2018, Volume 25, Issue 5, pp. 457 - 464
People with hepatitis C virus (HCV) infection other than genotype 1 represent a heterogeneous group. The aim of the phase 2 C-SCAPE study was to evaluate... 
clinical trial | INFECTIOUS DISEASES | PLUS RIBAVIRIN | ribavirin | MK-8742 | COMBINATION THERAPY | SOFOSBUVIR | MK-5172 | hepatitis | elbasvir | HCV INFECTION | TRIAL | TREATMENT-NAIVE | VIROLOGY | TREATMENT-EXPERIENCED PATIENTS | grazoprevir | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 11/2016, Volume 63, Issue 10, pp. 1320 - 1324
Journal Article
CLINICAL INFECTIOUS DISEASES, ISSN 1058-4838, 02/2018, Volume 66, Issue 3, pp. 464 - 474
With the advent of the direct-acting antiviral agents (DAM) for chronic hepatitis C infection, the treatment paradigm has dramatically changed, especially the... 
INFECTIOUS DISEASES | VIRUS-INFECTION | GRAZOPREVIR MK-5172 | hepatitis C | MICROBIOLOGY | IMMUNOLOGY | HCV INFECTION | TREATMENT-NAIVE | directly acting agents | SOFOSBUVIR PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | HCV | OPEN-LABEL TRIAL | ELBASVIR MK-8742 | ADVANCED LIVER-DISEASE | PHASE-2 TRIAL
Journal Article
JOURNAL OF VIRAL HEPATITIS, ISSN 1352-0504, 10/2017, Volume 24, Issue 10, pp. 895 - 899
Elbasvir (EBR; HCV NS5A inhibitor) and grazoprevir (GZR; HCV NS3/4A protease inhibitor) are approved as a fixed-dose combination to treat patients chronically... 
3 INFECTION | INFECTIOUS DISEASES | MK-8742 | SAFETY | SOFOSBUVIR | MK-5172 | RANDOMIZED-TRIAL | LABEL PHASE-2 TRIAL | COMBINATION | elbasvir | VIROLOGY | HEPATITIS-C VIRUS | TREATMENT-EXPERIENCED PATIENTS | hepatitis C virus | grazoprevir | genotype 3 | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, ISSN 1079-2082, 10/2017, Volume 74, Issue 19, pp. 1533 - 1540
Purpose. The chemistry, pharmacology, pharmacodynamics, pharmacokinetics, efficacy, safety, dosage, administration, and role of elbasvirgrazoprevir in the... 
MK-8742 | EFFICACY | SAFETY | hepatitis C | NS5A inhibitor | MK-5172 | COINFECTION | VIRUS GENOTYPE 1 | NS3/4A protease inhibitor | LABEL PHASE-2 TRIAL | RIBAVIRIN | elbasvir | TREATMENT-NAIVE | grazoprevir | PHARMACOLOGY & PHARMACY | INFECTION
Journal Article